Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Nirmatrelvir/Ritonavir and Ritonavir on Dabigatran PK in Healthy Participants
NCT05064800Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Nirmatrelvir and ritonavir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Pfizer. Primary endpoints: Plasma Dabigatran (Total) Maximum Plasma Concentration (Cmax) with PF-07321332/Ritonavir, Plasma Dabigatran (Total) Area Under the Curve to Infinity (AUCinf) with PF-07321332/Ritonavir and 1 more. Started Sep 2021; status: completed.
02
Drugs
Nirmatrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05064800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064800.